Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.73 +0.47 (+0.99%)
Official Closing Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
News headline image
What's Driving the Market Sentiment Around Novo Nordisk AS? ↗
 
Via Benzinga
News headline image
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem ↗
Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare. 
Via Benzinga
News headline image
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? ↗
Find out if the deal Omeros announced is enough of a reason to buy this stock. 
Via The Motley Fool
News headline image
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside ↗
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
News headline image
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
Via MarketBeat
Topics World Trade
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder ↗
Via Stocktwits
Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant ↗
Via Stocktwits
News headline image
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal ↗
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
News headline image
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026 ↗
The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. 
Via The Motley Fool
News headline image
Why Is Scholar Rock Stock Trading Lower On Monday? ↗
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
News headline image
Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
News headline image
Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
News headline image
The Smartest Growth Stock to Buy With $100 Right Now ↗
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
News headline image
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
News headline image
3 Top Healthcare Stocks to Buy in October ↗
Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders. 
Via The Motley Fool
Topics Economy Government Intellectual Property
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth ↗
Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability. 
Via Chartmill
News headline image
Should You Buy Novo Nordisk Right Now? ↗
The fallen pharma giant could make a big comeback in 2026. 
Via The Motley Fool
News headline image
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations ↗
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries. 
Via Benzinga
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in... 
Via MarketMinute
News headline image
Eastover Opens a Brand New $3.3 Million Novo Nordisk Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion ↗
Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio. 
Via Benzinga
News headline image
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗
The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company. 
Via Investor's Business Daily
Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch ↗
Via Stocktwits
Topics Economy Stocks
News headline image
What’s Driving The Super Rally In Akero Shares On Thursday Morning? ↗
Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right. 
Via Stocktwits
News headline image
Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO) ↗
Via The Motley Fool
News headline image
Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites ↗
Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing weight-loss drug sales. 
Via Benzinga
News headline image
Where Will LLY Be in 5 Years? ↗
After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030. 
Via The Motley Fool
Topics World Trade
News headline image
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss ↗
Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results. 
Via Benzinga
News headline image
2 Beaten-Down Stocks Primed for a Comeback ↗
The market is sleeping on these stocks, but you don't have to. 
Via The Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.